Manager TitleAgeSince
Director of Finance/CFO - 01/05/2023
Investor Relations Contact - -
Comptroller/Controller/Auditor - 10/10/2022
Director TitleAgeSince
Chairman 75 29/04/2021
Director/Board Member 63 10/08/2022
Date Insider Type Main position Quantity % Market Cap.
31/05/23Free

Chief Executive Officer

671,800 0.5200%
04/05/23Sell

Chief Executive Officer

8,419 0.0065%
04/05/23Sell

Chief Executive Officer

22,238 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-1.05% - - 235M
-0.48%+4.75%+53.82%+17.81% 3.18B
-0.20%-1.69%-16.21%+7.37% 2.79B
-0.43%-2.11%+33.79%+19.59% 1.9B
+3.39%-0.21%+95.63%+155.06% 1.2B
-0.44%-0.44%-2.15%-7.43% 709M
-1.23%-26.29%+157.05%+284.84% 691M
0.00%-5.13%-46.38%-73.76% 401M
0.00%0.00%-6.54%-10.06% 393M
0.00%0.00%-1.83%-10.79% 369M
Average +0.08%-3.62%+29.69%+42.51% 1.29B
Weighted average by Cap. +0.04%-1.10%+33.49%+39.03%
Logo Arix Bioscience plc
Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.
Employees
9
  1. Stock Market
  2. Stocks
  3. ARIX Stock